Click to Learn More About AtriCure
AtriClip
LAA Exclusion System, the most widely implanted LAA management
Insist on Eliminating the Source!
Don’t Just Manage the Risk,
device globally (30,000+), specifically indicated for LAA exclusion.
Synergy
for the treatment of Persistent
The first and only device approved
and Longstanding Persistent Afib
Invest in the Global Leader
In Afib Solutions
Join Our
World Class Team

AtriCure: Committed to Atrial Fibrillation Treatment and Solutions

AtriCure is your partner in atrial fibrillation solutions. Our research and rigorous atrial fibrillation clinical trials have led to innovations in ablation technology to treat atrial fibrillation with lasting solutions. Our Synergy Ablation System is the first and only device approved by the Food and Drug Administration for the surgical treatment of persistent atrial fibrillation and longstanding persistent atrial fibrillation in patients undergoing open heart procedures simultaneously. In addition, we pioneered the AtriClip®, a left atrial appendage occlusion, device that is the most widely implanted for left atrial appendage management worldwide. It is our passion to collaborate with surgeons to make surgeries like the Maze IV simpler to perform and be reproducible by more doctors around the world. Through continued commitment to product innovation and education grounded in clinical science, we’re working to reduce the global atrial fibrillation epidemic.

National News

AtriCure Reports Second Quarter 2014 Financial Results and Updates 2014 Outlook

07.24.2014
Revenue of $26.5 million – up 29.8% U.S. sales of $19.9 million – up 28.8% International sales of $6.6 million – up 32.9%; 29.1% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 24, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation (“Afib”) medical device provider, today announced financial results for the second quarter of 2014. “We are pleased with our performance in the second quarter in which we delivered solid revenue growth while integrating Estech that further positions us as a leader in the treatment of Afib. We also continued to e...

Read More

International News

In the Fight Against Atrial Fibrillation, AtriCure Launches Maze IV Training Program in Europe

10.01.2013
AMSTERDAM, Netherlands--(BUSINESS WIRE)--Oct. 1, 2013-- AtriCure, Inc. (Nasdaq: ATRC), is partnering with leading atrial fibrillation (Afib) centers and thought leaders across Europe to provide best-in-class training on surgical ablation. The launch of an international Maze IV Training program will take place on October 1 in Germany at Sana Stuttgart Cardiac Surgery Center, one of six initial European hospitals selected to participate in this important initiative. This initial course will be led by surgeons recognized as experts in the field of surgical treatment for Afib. They include: James L. Co...

Read More